Skip to main content.

Ken P. Byrd, D.O.

Kenneth Byrd
Assistant Professor, Hematologic Malignancies and Cellular Therapeutics

Professional Background

Dr. Byrd is an Assistant Professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas. He spends much of his clinical time on several inpatient hematology services at the central KUMC campus. This includes the acute leukemia and consultative hematology services. It also includes the hematology teaching service in which he provides patient care and teaches KUMC residents, fellows and medical students. He also sees patients with acute leukemia at the Cancer Center.

Dr. Byrd completed medical school at the Kansas City University of Medicine. He completed his Internal Medicine Residency at the University of Kansas in Wichita where he also served as chief resident. He proceeded to complete his Hematology andamp; Oncology Fellowship at the University of Tennessee where he also served as chief fellow.

Education and Training
  • DO, Internal Medicine, Kansas City University of Medicine and Biosciences, Kansas City, Missouri
  • Clinical Fellowship, Hematology & Oncology, University of Tennessee Health Science Center/The West Cancer Center, Memphis, Tennessee
  • Residency, Internal Medicine, University of Kansas, Wichita, Kansas
Licensure, Accreditations & Certifications
  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Kenneth Byrd, Kansas Board of Healing Arts
  • Medical Oncology, ABIM
Professional Affiliations
  • ECOG-ACRIN Leukemia Committee, Member, 2020 - Present
  • Conflict of Interest Research Committee, Member, 2019 - 2020
  • KUMC Med Safety Committee, Member, 2019 - 2020
  • American Society of Clinical Oncology, Member, 2016 - Present
  • American Society of Hematology, Member, 2016 - Present



His research interests include acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). He serves on the ECOG-ACRIN leukemia national committee and is currently the institutional principal investigator on several ongoing acute leukemia clinical trials.

Current Research and Grants
  • A phase II study of inotuzumab ozogamicin followed by blinatumomab for phnegative CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease, Alliance for Clinical Trials in Oncology, PI
  • A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-Cell ALL, Alliance for Clinical Trials in Oncology, PI
  • A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy, Alliance for Clinical Trials in Oncology, PI
  • Byrd, Kenneth., P., Vontela, Namratha., R., McCullar, Brennan, Martin, Mike., G.. 2017. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma. Anticancer Research, 37 (12), 6839-6843
  • Byrd, Kenneth, Nagahawatte, Panduka, Martin, Michael., Gary, Stein, Matthew., K, Patel, Kruti, Schwartzberg, Lee., Steven, Vanderwalde, Ari., M.. 2017. Correlation between PD-L1 expression level and clinical benefit in 204 patients across malignancies at a single institution.. Journal of Clinical Oncology, 35 (15_suppl), e14573-e14573.
  • Karri, Saradasri, Stein, Matthew., K., Patel, Kruti, Crawley, Melissa, Vontela, Namratha., Reddy, Alloway, Taylor, Morris, Lindsay., Kaye, Mays, John, Hare, Felicia, Prouet, Philippe, Byrd, Kenneth., P., Wiedower, Eric, Chandler, Jason., Claud, Fenton, Moon., Jung, Weksler, Benny, Schwartzberg, Lee., Steven, Martin, Michael., Gary. 2017. In silico analysis of DNA damage repair variants in advanced NSCLC patients (pts) to predict response to platinum-based chemotherapy (PBC).. JOURNAL OF CLINICAL ONCOLOGY, 35 (15), e20582.
  • Byrd, Kenneth. 2017. In silico analysis of non-synonymous SNPs (nsSNPs) and outcomes in non-small cell lung cancer (NSCLC) patients (pts) treated with immunotherapy (IT). Journal of Clinical Oncology, 35 (15_suppl), e14563-e14563.
  • Kohia, M, Brackle, J, Byrd, K, Jennings, A, Murray, W, Wilfong, E. 2008. Effectiveness of physical therapy treatments on lateral epicondylitis.. Journal of Sport Rehabilitation, 17 (2), 119-36